efficacy against a subset of hematological malignancies 1,2 , yet its autologous nature and ineffectiveness against epithelial and solid cancers limit widespread application. To overcome these limitations, targeted nucleases have been used to disrupt checkpoint inhibitors and genes involved in alloreactivity 3-6 . However, the production of allogeneic, "off-the-shelf" T cells with enhanced function requires multiplex genome editing strategies that risk off-target effects, chromosomal rearrangements, and genotoxicity due to simultaneous double-strand break (DSB) induction at multiple loci 7-10 . Moreover, it has been well documented that DSBs are toxic lesions that can drive genetic instability 11,12 .
In the context of pmSTOP, non-target edits preclude premature stop codon formation, thereby lowering the efficiency of protein knockout, and instead create potentially undesirable amino acid changes.
To assess the performance of both pmSTOP introduction and splice-site disruption, we designed a panel of single guide RNAs (sgRNA) to convert amino acid codons to pmSTOPs or to disrupt splice donor (SD) and acceptor (SA) sequences within PDCD1, TRAC, and B2M (Figure   1a , e, i; Supplemental Table 1 ). Individual sgRNAs were co-delivered as chemically modified RNA oligonucleotides 23 with first generation BE3 13 or BE4 22 mRNA to T cells by electroporation.
Target C to T editing rates were assessed by Sanger sequencing and EditR, an analysis software developed by our group to expedite and economize analysis of base editing at the genetic level 24 (baseeditr.com).
First, we targeted the checkpoint gene PDCD1 (PD-1) by designing eight sgRNAs; three of which were predicted to introduce pmSTOP codons, two targeted disruption of SD sites (GT:CA), and three targeted disruption of SA sites (AG:TC) (Figure 1a) . We found that co-delivery of sgRNAs with BE3 or BE4 mRNA mediated measurable editing of target Cs at all target loci, with several candidate sgRNAs exhibiting significantly higher rates of editing than others (Figure   1b , Supplemental Data 2). Specifically, we found that targeting the SD site of PDCD1 exon 1 resulted in the highest rate of target C to T editing with both BE3 (51.3 ± 7.0%, M ± SD) and BE4 (63.7 ± 2.1%) mRNA (Figure 1b) . The next two most efficient sgRNAs targeted the exon 3 SA site (32.6 ± 5.5% for BE3; 36.0 ± 4.0% for BE4) and a candidate pmSTOP site in exon 2 (37.1 ± 1.2% for BE3; 48.5 ± 3.7% for BE4) (Figure 1b) . To determine whether genetic editing results in protein loss we assessed expression of PD-1 protein by flow cytometry. Concordant with our genetic analysis, targeting PDCD1 exon 1 SD resulted in the highest rate of protein loss (69.5 ± 7.0% for BE3; 78.6 ± 4.1% for BE4), followed by exon 3 SA (40.6 ± 7.8% for BE3; 44.7 ± 3.8% for BE4), and exon 2 pmSTOP (37.9 ± 3.4% for BE3; 51.5 ± 9.0% for BE4) (Figure 1c) .
Informed by our PDCD1 results, we designed a focused panel of sgRNAs targeting TRAC (Figure 1e ). Here we found that C to T conversion was highest at the exon 1 SD site (47.6 ± 4.6% for BE3; 60.0 ± 11.3% for BE4) and exon 3 SA site (40.3 ± 9.7% for BE3; 62.3 ± 11.0% for BE4), with BE4 exhibiting higher editing rates than BE3 at each target (Figure 1f ). Efficient editing was also observed at two pmSTOP candidate sites in exon 3, albeit at lower efficiencies than that of either splice-site disrupting sgRNA (Figure 1f ). Both the exon 1 SD and exon 3 SA sites were edited at similar frequencies, yet disruption of the exon 3 SA site resulted in the highest rate of TCR disruption as measured by loss of cell-surface CD3 expression (69 ± 15.3% for BE3; 83.7 ± 5.8% for BE4) (Figure 1g) .
We next targeted B2M using a similar strategy (Figure 1i ). BE4 mRNA delivered with an sgRNA targeting the exon 1 SD site showed the most efficient C to T conversion of the target base (58.3 ± 2.5% for BE3; 70.3 ± 3.2% for BE4) (Figure 1j) , resulting in efficient knockout of B2M protein (79.1 ± 1.3% for BE3; 80.0 ± 3.2% for BE4) (Figure 1k) . We also identified a candidate pmSTOP site in exon 2 that resulted in relatively efficient C to T editing (43.3 ± 5.7% for BE3; 55.7 ± 5.0% for BE4), and protein knockout (56.2 ± 5.1% for BE3; 61.5 ± 1.8% for BE4) (Figure 1j, k) . Notably, targeting the SA site of noncoding exon 3 produced efficient C to T editing but did not result in a detectable reduction in protein expression (Figure 1j, k) .
Non-target editing (i.e. C to A or G) has been reported for BE3 13 and is reduced with BE4, which contains a second uracil glycosylase inhibitor (UGI) fused in series at the C-terminus 22 . We evaluated non-target editing rates for all Cs within the editing window (predominantly bases 4-8 of protospacer) of our most efficient sgRNAs with BE3 and BE4. As expected, BE4 showed reduced non-target editing compared to BE3 at all loci (-14% ± 6.6%, P < 2.2e-16, Paired oneway t-test) (Figure 1d, 22 .
Toward our goal of validating a multiplex editing strategy that could be utilized to generate allogeneic, "off-the-shelf" T cells with enhanced function, we co-delivered our top sgRNA for each gene along with first-generation BE3 or BE4 mRNA. Surprisingly, editing efficiency at each target was substantially reduced for both BE3 and BE4 when delivered in a multiplex setting (Supplemental Data 4). To determine if the reduced editing efficiency was due to low protein levels, we delivered equal doses of BE3, BE4, and nuclease active Streptococcus pyogenes Cas9 (SpCas9) mRNA to T cells and measured protein expression at 24hrs and 48hrs after electroporation. Strikingly, while Cas9 protein expression was readily detectable at these time points, BE3 and BE4 protein were undetectable (Supplemental Data 5). To address this issue, we first delivered BE3 and BE4 mRNA at a dose 2x higher (3 µg) than that used in our initial multiplex experiments (1.5 µg). This strategy improved editing efficiency at each locus, but the efficiencies were still lower than those observed in our single gene targeting experiments (Figure   2a ).
During the course of these experiments, independent reports emerged identifying problems related to the use of first-generation BE3 and BE4 expression vectors that severely reduce both transcriptional and translational efficiency in human cells 17, 25 . To circumvent these issues, we delivered purified BE4 protein as a ribonucleoprotein (RNP) complex with our most effective sgRNA for each target. By optimizing our electroporation protocol for RNP delivery, we found that BE4 RNP mediated improved editing efficiency over a 2x dose of first-generation BE4 mRNA (Figure 2c ). Next, we codon optimized the sequence of BE4 (coBE4) and delivered mRNA at both our standard dose (1.5 µg) and a higher dose (4 µg) with all three of our optimal sgRNAs. At both mRNA doses, we achieved substantially higher rates of multiplex target C to T editing at all three loci across multiple independent T cell donors, exceeding 90% in some instances (Figure   2a ). Non-target editing observed with first-generation BE3 and BE4 mRNA was reduced slightly when using BE4 RNP, but even further reduced with both doses of coBE4 mRNA (Figure 2a) .
We next evaluated the rate of indel formation at each target site after multiplex base editing and, in accordance with previous studies, found lower rates of indel formation at each site with all forms of BE4 compared to BE3 and Cas9 nuclease (Figure 2b (Figure 2e ).
While first-generation BE4 mRNA generated an endpoint cell population with a diverse combination of knockout phenotypes, the frequency of triple knockout cells was low (21.9 ± 1.1%).
The proportion of triple knockout cells was substantially higher using BE4 RNP (68.6 ± 0.37%), and even further increased with coBE4 mRNA at 1.5 µg (86.6 ± 3.75%) and 4 µg (89.57 ± 4.2%) (Figure 2f ).
Nuclease-mediated multiplex editing has been reported to generate undesired translocations in human T cells 3 . As base editing substantially reduces the frequency of DSB formation, we reasoned that translocations should likewise be reduced using our base editing approach. To test our hypothesis, we used droplet digital PCR (ddPCR) assays that span the junction of several possible translocation outcomes (Figure 3a) . Following co-delivery of our three optimal sgRNA with either spCas9 nuclease RNP or mRNA, we were able to detect three translocation outcomes: B2M:TRAC, PDCD1:B2M, and PDCD1:TRAC (Figure 3b, c, d) . In all cases, spCas9 mRNA resulted in the highest rate of translocation frequency, with translocations between B2M and TRAC being most frequent (1.57 ± 0.07%) (Figure 3b, c, d) . In stark contrast, the B2M:TRAC and PDCD1:TRAC outcomes were not detected in cell populations receiving BE4 RNP or either dose of coBE4 mRNA with our optimal sgRNAs (Figure 3b, c, d) . In a single replicate from one donor, the PDCD1:B2M assay gave rise to two positive droplets with low-dose coBE4 mRNA (calculated frequency = 0.003 ± 0.006%). Because no positive droplets were detected with BE4 RNP or high-dose coBE4 mRNA, these may be artifactual (Figure 3c ).
Off-target (OT) DSB induction is another important challenge facing nuclease platforms 26 .
To determine the specificity of our optimal sgRNAs, we delivered each individually with spCas9 nuclease or BE4 mRNA and evaluated editing at the top 10 predicted OT sites by NGS (Supplemental Table 2 ). No editing was observed at any of the predicted B2M or TRAC OT sites in either the spCas9 nuclease or BE4 treatment conditions (Supplemental Data 7). At the predicted PDCD1 OT sites we observed a single OT edit with an indel frequency of 13.0% using spCas9 mRNA (Supplemental Data 7). Strikingly, C to T editing at this site was only 0.9% with BE4 mRNA, and indel formation was near the low detection limit of our assay (0.2%)
(Supplemental Data 7).
We next sought to determine whether multiplex knockout T cells generated using our base editing strategy retain cytokine functionality and are capable of mediating target cell killing when equipped with a CAR. We performed phenotypic evaluation of both electroporation pulse control and coBE4 knockout T cells with and without a CD19-specific CAR by analyzing markers of differentiation 27 . Both untransduced and CAR-transduced T cells exhibited similar differentiation phenotypes, with the fractions of effector and memory populations similar between control and coBE4 knockout T cells (Figure 4a) . CAR transduction and cell expansion were also comparable between pulse and coBE4 mRNA groups (Supplemental Data 8). Following activation, a high frequency of both untransduced and CAR-transduced coBE4 knockout T cells exhibited robust production of cytokines IL-2, TNFα, and IFNγ (Figure 4b) . Cytokine polyfunctionality was similarly retained following the multiplex editing process (Figure 4c ). Collectively, these data demonstrate that multiplex coBE4 editing combined with CAR transduction did not negatively impact T cell phenotype or function. Finally, to determine if coBE4 knockout T cells equipped with the CD19 CAR retained the ability to kill target cells, we conducted in vitro co-culture assays with non-target CD19 neg /PD-L1 neg K562; target CD19 pos /PD-L1 neg Raji; and target CD19 pos /PD-L1 pos Raji engineered to overexpress PD-L1, which would normally act to inhibit killing by T cells expressing cell surface PD-1. Both control and coBE4 knockout T cells mediated specific killing of CD19 pos but not CD19 neg target cells (Figure 4d ). However, only coBE4 knockout T cells were able to achieve significant killing of CD19 pos /PD-L1 pos target cells, with the efficiency of killing equivalent to that of CD19 pos /PD-L1 neg target cells (Figure 4d ).
As we come to better understand the requirements for successful cell-based immunotherapy and gene therapy, and as enthusiasm grows for the production of universal, allogeneic cells, highly multiplexed gene editing will likely become more commonplace. However, it has been well documented that DSBs are toxic lesions that can drive genomic instability and cell death 11, 12 . This is a lesser concern when engineering cells for research but could lead to transformation or reduced function when gene editing cells for therapeutic use. Our concerns surrounding DSBs are further heightened in the context of multiplex gene editing where multiple, simultaneous DSBs can compound toxicity and increase the potential for detrimental translocations. To overcome these issues, we have implemented the use of base editor technology for multiplex T cell engineering and demonstrate that splice site disruption through base editing offers an efficient and safer approach compared to the use of DSB-inducing targeted nucleases.
Interestingly, we find both higher rates of non-target editing and indel formation when using BE4 RNP compared to coBE4 expressed from transfected mRNA. This observation may be due to the extended BE4 residence time achieved when expressed at high levels from a stable mRNA as opposed to direct BE4 protein delivery. As even free UGI has been shown to reduce both indel frequency and non-target editing in the context of BE3 28 , the extended residence time achieved by mRNA delivery may allow BE4 UGI domains additional capacity to mitigate DSB formation and non-target editing 28 .
In our current study we utilized lentiviral delivery of CD19-specific CAR, which is the current industry standard in CAR-T therapy. However, this approach has many drawbacks, including the risk of insertional mutagenesis, variable CAR expression, and gene silencing [29] [30] [31] .
To overcome these issues, a number of groups have demonstrated high efficiency, site-specific integration using Cas9 nuclease along with rAAV-delivered DNA donor templates for homologous recombination (HR). This raises the possibility that BE4 could be deployed to safely and efficiently knockout multiple genes with simultaneous introduction of therapeutic transgenes in a sitespecific fashion using rAAV and Cas9 orthologs, such as Staphylococcus aureus Cas9 (SaCas9) or Francisella novella Cas9 (FnCas9) 32, 33 . The application of Cas9 orthologs would allow for simultaneous use of distinct sgRNAs specific to BE4 and Cas9 nuclease without concerns of cross-utilization. Alternatively, it has been demonstrated that a DNA nick can be used to stimulate HR using naked DNA or rAAV as a DNA donor molecule, albeit with lower efficiency 34 . This provocatively highlights the potential of BE4 to mediate gene knockout through deaminase activity, while simultaneously mediating HR through its nickase function. In this scenario, the sgRNA binding sites may require an absence of cytosines within the base editing window to prevent loss of Cas9 binding due to sequence changes through C to T conversion.
One notable difference between the use of base editors and targeted nucleases is the number of potential outcomes from the editing event. Nuclease-mediated DSBs are repaired through the highly variable non-homologous end joining (NHEJ) pathway, resulting in a spectrum of indels; some of which will not introduce frame-shift mutations and will thus have unknown significance to gene expression and function. Alternatively, our base editing approach has a limited number of outcomes, all resulting in the loss of function of the native splice donor or acceptor, even when considering non-target editing. Yet it is important to consider that disruption of the native splice site may not always result in a nonfunctional product, given that alternative or cryptic splicing could maintain the biological function of a gene.
Translocation analysis using small ddPCR amplicons (>200bp) spanning the sgRNA target site demonstrated that base editing with optimal reagents virtually eliminates detectable translocations, whereas Cas9 nuclease produces numerous translocations, some at frequencies as high as 1.5%. Notably, larger deletions were also identified at the site of translocation through Sanger sequencing of subcloned junction PCR amplicons (~500bp) from SpCas9-treated cells (Supplemental Data 9). These data suggest the presence of more complex genomic rearrangements similar to those reported previously 9,10 that are not detected by our current ddPCR assays. Considering the variability in efficiency of nucleic acid delivery between cells by electroporation, it is possible that cells receiving high levels of SpCas9/sgRNA may harbor translocations more frequently.
Although we demonstrate that BE4 substantially reduces DSB induction compared to SpCas9 nuclease and does not produce detectable translocations, the potential remains for undesirable events to occur. For instance, it is possible that the rAPOBEC1 of BE4 could nonspecifically edit cytosines in single-stranded DNA during DNA replication 35 . Additionally, the UGIs of BE4 could potentially inhibit uracil DNA glycosylases in a nonspecific fashion, thereby hindering base excision repair of naturally and frequently occurring cytosine deamination in normal mammalian cells 36 . Further studies investigating these potential events should be undertaken prior to clinical translation of base edited cells, though it may be challenging to definitively document such unintended occurrences. Despite these areas of uncertainty, the base editor platform represents a novel approach for highly efficient multiplex engineering of therapeutic primary cells with an improved safety profile compared to current nuclease technologies.
METHODS

Cloning & Viral Production
DNA sequences for CD19 chimeric antigen receptor linked by a T2A to RQR8 were synthesized as gBlock Gene Fragments (Integrated DNA Technologies [IDT]). Fragments were Gibson 
CD3+ T cell Isolation
Peripheral blood mononuclear cells (PBMCs) were isolated from Trima Accel leukoreduction system (LRS) chambers using ammonium chloride-based red blood cell lysis. CD3+ T cells were isolated from the PBMC population by immunomagnetic negative selection using the EasySep Human T cell Isolation Kit (STEMCELL Technologies). T cells were frozen at 10-20x10 6 cells per 1 mL of Cryostor CS10 (STEMCELL Technologies) and thawed into culture as needed.
T cell culture
T cells were cultured at 1x10 6 cells per 1 mL in OpTmizer CTS T cell Expansion SFM containing 2.5% CTS Immune Cell SR (ThermoFisher), L-Glutamine, Penicillin/Streptomycin, N-Acetyl-L-cysteine (10 mM), IL-2 (300 IU), IL-7 (5 ng), and IL-15 (5 ng) at 37°C and 5% CO2. T cells were activated with Dynabeads Human T-Activator CD3/CD28 (ThermoFisher) at a 2:1 bead:cell ratio for 48-72 hours prior to electroporation.
T cell electroporation
After 48 hours, Dynabeads were magnetically removed and cells washed with PBS once prior to resuspension in appropriate electroporation buffer. For singleplex experiments, 3x10 5 T cells were electroporated with 1 µg of chemically modified sgRNA (Synthego, Menlo Park, CA) and 1.5 µg SpCas9, BE3, or BE4 mRNA (TriLink Biotechnologies) in a 10 µL tip using the Neon Transfection System (ThermoFisher) under the following conditions: 1400 volts, pulse width of 10 milliseconds, 3 pulses. The 4D-Nucleofector (Lonza) and P3 kit was used for multiplex studies with 1x10 6 T cells per 20 µL cuvette, 1.5-6 µg BE mRNA as indicated, and the Nucleofector program EO-115. RNP were generated by incubation of 10 µg SpCas9 protein (IDT, Coralville Iowa), or 12 µg BE4 protein (Aldevron, Fargo) with 3 µg of chemically modified sgRNA (Synthego) for 15 min at room temperature and electroporated using the Nucleofector program EH-115. T cells were allowed to recover in antibiotic-free medium at 37°C, 5% CO2 for 20 minutes following gene transfer, and were then cultured in complete CTS OpTmizer T cell Expansion SFM as described above.
Lentiviral Transduction
T cells were transduced 24 hours after transfection with pRRL-MND-CAR19-RQR8 lentiviral vector (UMN Viral Vector & Cloning Core) at an MOI of 20 by spinfection on Retronectin (Takara)coated plates.
Genomic DNA Analysis
Genomic DNA was isolated from T cells 5 days post-electroporation by spin column-based purification. Base editing efficiency was analyzed on the genomic level by PCR amplification of CRISPR-targeted loci, Sanger sequencing of the PCR amplicons, and subsequent analysis of the Sanger sequencing traces using the web app EditR as previously described (baseeditr.com) 24 .
Next generation sequencing (NGS) was also performed on the same PCR amplicons.
Next Generation Sequencing & Analysis
Primers with Nextera universal primer adaptors (Illumina) were designed to amplify a 375-425 bp site surrounding the region of interest using Primer3Plus. Genomic DNA was PCR-amplified using 
Flow Cytometry
Prior to flow cytometry, singleplex PDCD1 disrupted T cells were re-stimulated using CD3/CD28 Dynabeads for 48 hours as described above. In multiplex experiments with TRAC knockout, T cells were activated with Phorbol 12-myristate 13-acetate (PMA; 100 ng/mL; Sigma-Aldrich) and 
Immunoblotting assay
Proteins were isolated from 1x10 6 cells in complete RIPA buffer with protease and phosphatase inhibitors (Sigma-Aldrich, COEDTAF-RO, P5726, and P0044). Total protein was quantified using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific Inc., 23225) according to the manufacturer's protocol. Protein samples were run and analyzed on the Wes platform after being denatured at 95°C for 5 minutes according to the manufacturer's protocol (ProteinSimple).
Primary antibodies against SpCas9 (Cell Signaling, #14697) and actin (Cell Signaling, #8457) were used at 1:100 and 1:50 dilutions, respectively, in kit-supplied buffer and platform-optimized secondary antibodies were purchased from Protein Simple.
Data analysis and visualization
All statistical analyses were performed in R studio. The level of significance was set at α = 0.05. 
